Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals

Inflammation Research

Volumn 60, Issue 7, 2011, Pages 633-642

  Iagalo Miguel, Lediana ^a   Almeida, Camila B ^a   Traina, Fabiola ^a   Canalli, Andreia A ^a   Dominical, Venina M ^a   Saad, Sara T O ^a   Costa, Fernando F ^a   Conran, Nicola ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

cGMP Cytokine; Inflammation; Leukocyte; Sickle cell anemia; Vaso occlusio

Indexed keywords

BAY 41 2271; BAY 73 6691; CD11B ANTIGEN; CYCLIC GMP; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANYLATE CYCLASE ACTIVATOR; INTERLEUKIN 8; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PHOSPHODIESTERASE; PHOSPHODIESTERASE 9A; PHOSPHODIESTERASE INHIBITOR; RECOMBINANT INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CELL SURFACE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE ADHERENCE; LEUKOCYTE ADHERENCE INHIBITION; MALE; NEUTROPHIL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SICKLE CELL ANEMIA;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; CELL ADHESION; CYCLIC GMP; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; YOUNG ADULT;

EID: 80051672433     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-011-0315-8     Document Type: Article

References (48)

1. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The cooperative study of sickle cell disease. Blood. 1994;84:643-9. (Pubitemid 24215969)
2. Kinney TR, Sleeper LA, Wang WC, Zimmerman RA, Pegelow CH, Ohene-Frempong K, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The cooperative study of sickle cell disease. Pediatrics. 1999;103:640-5. (Pubitemid 29274513)
3. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. N Eng J Med. 2000;342:83-9. (Pubitemid 30036599)
4. Lanaro C, Franco-Penteado CF, Albuqueque DM, Saad ST, Conran N, Costa FF. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol. 2009;85:235-42.
5. Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol Oncol Clin N Am. 2005;19:771-84. (Pubitemid 41427109)
6. Conran N, Costa FF. Hemoglobin disorders and endothelial cell interactions. Clin Biochem. 2009;42:1824-38.
7. Turhan A, Jenab P, Bruhns P, Ravetch JV, Coller BS, Frenette PS. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood. 2004;103:2397-400. (Pubitemid 38326264)
8. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci USA. 2002;99: 3047-51.
9. Assis A, Conran N, Canalli AA, Lorand-Metze I, Saad ST, Costa FF. Effect of cytokines and chemokines on sickle neutrophil adhesion to fibronectin. Acta Haematol. 2005;113:130-6. (Pubitemid 40522817)
10. Canalli AA, Franco-Penteado CF, Traina F, Saad ST, Costa FF, Conran N. Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease. Eur J Haematol. 2007;79:330-7. (Pubitemid 47390136)
11. Fadlon E, Vordermeier S, Pearson TC, Mire-Sluis AR, Dumonde DC, Phillips J, et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood. 1998;91:266-74.
12. Wun T, Cordoba M, Rangaswami A, Cheung AW, Paglieroni T. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol. 2002;24: 81-8. (Pubitemid 35013546)
13. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol. 2009;84:618-25.
14. Conran N, Ferreira HH, Lorand-Metze I, Thomazzi SM, Antunes E, de Nucci G. Nitric oxide regulates human eosinophil adhesion mechanisms in vitro by changing integrin expression and activity on the eosinophil cell surface. Br J Pharmacol. 2001;134:632-8. (Pubitemid 32977908)
15. Conran N, Gambero A, Ferreira HH, Antunes E, de Nucci G. Nitric oxide has a role in regulating VLA-4-integrin expression on the human neutrophil cell surface. Biochem Pharmacol. 2003;66:43-50. (Pubitemid 36724898)
16. Canalli AA, Franco-Penteado CF, Saad STO, Conran N, Costa FF. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologica. 2008;93:605-9.
17. Mack AK, McGowan Ii VR, Tremonti CK, Ackah D, Barnett C, Machado RF, et al. Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study. Br J Haematol. 2008;142:971-8.
18. Schmidt HH, Schmidt PM, Stasch JP. NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol. 2009;191:309-39.
19. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58: 488-520. (Pubitemid 44394910)
20. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010;62:525-63.
21. Almeida CB, Traina F, Lanaro C, Canalli AA, Saad ST, Costa FF, et al. High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils. Br J Haematol. 2008;142:836-44.
22. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212-5. (Pubitemid 32216593)
23. Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol. 2005;68:1775-81. (Pubitemid 41654360)
24. Montes RA, Eckman JR, Hsu LL, Wick TM. Sickle erythrocyte adherence to endothelium at low shear: role of shear stress in propagation of vaso-occlusion. Am J Hematol. 2002;70:216-27. (Pubitemid 34680682)
25. Rodgers GP, Schechter AN, Noguchi CT, Klein HG, Nienhuis AW, Bonner RF. Periodic microcirculatory flow in patients with sickle-cell disease. N Eng J Med. 1984;311:1534-8. (Pubitemid 15223252)
26. English D, Andersen BR. Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Methods. 1974; 5:249-52.
27. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982;78: 206-9. (Pubitemid 12171880)
28. Benkerrou M, Delarche C, Brahimi L, Fay M, Vilmer E, Elion J, et al. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood. 2002; 99:2297-303. (Pubitemid 34525412)
29. Finnegan EM, Barabino GA, Liu XD, Chang HY, Jonczyk A, Kaul DK. Small-molecule cyclic alpha V beta 3 antagonists inhibit sickle red cell adhesion to vascular endothelium and vasoocclusion. Am J Physiol Heart Circ Physiol. 2007;293: H1038-45. (Pubitemid 47254203)
30. Finnegan EM, Turhan A, Golan DE, Barabino GA. Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion. Am J Hematol. 2007;82:266-75. (Pubitemid 46564320)
31. Zennadi R, Chien A, Xu K, Batchvarova M, Telen MJ. Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood. 2008;112:3474-83.
32. Conran N, Saad ST, Costa FF, Ikuta T. Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colonystimulating factor in sickle cell disease. Ann Hematol. 2007;86: 255-61. (Pubitemid 46351400)
33. Croizat H. Circulating cytokines in sickle cell patients during steady state. Br J Haematol. 1994;87:592-7. (Pubitemid 24230028)
34. Canalli AA, Proenca-Ferreira R, Franco-Penteado CF, Traina F, Sakamoto TM, Saad ST, et al. Participation of the Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin. Haematologica. 2011 [Epub ahead of print].
35. Kobayashi Y. The role of chemokines in neutrophil biology. Front Biosci. 2008;13:2400-7. (Pubitemid 351599693)
36. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8:533-44. (Pubitemid 351913679)
37. Lum AF, Wun T, Staunton D, Simon SI. Inflammatory potential of neutrophils detected in sickle cell disease. Am J Hematol. 2004;76:126-33. (Pubitemid 38702555)
38. Okpala I. Leukocyte adhesion and the pathophysiology of sickle cell disease. Curr Opin Hematol. 2006;13:40-4.
39. von Andrian UH, Chambers JD, McEvoy LM, Bargatze RF, Arfors KE, Butcher EC. Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte beta 2 integrins in vivo. Proc Natl Acad Sci USA. 1991;88:7538-42. (Pubitemid 21915188)
40. Smalley DM, Ley K. L-selectin: mechanisms and physiological significance of ectodomain cleavage. J Cell Mol Med. 2005; 9:255-66.
41. Menezes GB, Lee WY, Zhou H, Waterhouse CC, Cara DC, Kubes P. Selective down-regulation of neutrophil Mac-1 in endotoxemic hepatic microcirculation via IL-10. J Immunol. 2009; 183:7557-68.
42. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol. 2007;25:619-47. (Pubitemid 46697919)
43. Fagerholm SC, Varis M, Stefanidakis M, Hilden TJ, Gahmberg CG. alpha-chain phosphorylation of the human leukocyte CD11b/ CD18 (Mac-1) integrin is pivotal for integrin activation to bind ICAMs and leukocyte extravasation. Blood. 2006;108:3379-86.
44. Hogg N, Leitinger B. Shape and shift changes related to the function of leukocyte integrins LFA-1 and Mac-1. J Leukoc Biol. 2001;69:893-8. (Pubitemid 32577889)
45. Bischoff E, Stasch JP. Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition. Circulation. 2004;110:e320-1. author reply e320-321.
46. Mullershausen F, Russwurm M, Friebe A, Koesling D. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation. 2004;109: 1711-3.
47. Machado RF, Martyr S, Kato GJ, Barst RJ, Anthi A, Robinson MR, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol. 2005;130:445-53. (Pubitemid 43899595)
48. Huang LJ, Yoon MH, Choi JI, Kim WM, Lee HG, Kim YO. Effect of sildenafil on neuropathic pain and hemodynamics in rats. Yonsei Med J. 2010;51:82-7.